Showing 2261-2270 of 10402 results for "".
How Much Are You Leaving on the Table?
https://practicaldermatology.com/topics/practice-management/how-much-are-you-leaving-on-the-table/21444/How to improve your after-tax financial efficiency for 2014.Update on the Treatment of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/update-on-the-treatment-of-actinic-keratoses/21630/From mainstay therapies to newly approved agents, treatment options for actinic keratoses are growing.Emerging Therapies in the Evolving Biologic Platform for Psoriasis Treatment
https://practicaldermatology.com/topics/practice-management/emerging-therapies-in-the-evolving-biologic-platform-for-psoriasis-treatment/21377/The Importance of the Atopic Dermatitis Pipeline
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atopMental Health Implications in Psoriasis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mental-health-implications-in-psoriasis/48771/Andrew Blauvelt, MD, MBA, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about how IL-17 inhibition can reduce suicidal ideation and behavior in psoriasis patients, as covered in the Journal of the American Academy of Dermatology article “Mental health outcomes in paTesting for Persistent Atopic Dermatitis in Pediatric Patients
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37151/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains key considerations when testing for persistent atopic dermatitis in children.Psoriasis Therapeutics and Moving to Private Practice
https://practicaldermatology.com/series/the-practical-dermatology-podcast/program-name/35733/H.L. Greenberg, MD, discusses his recent Practical Dermatology article on the various benefits of different psoriasis therapeutics, and Tina Bhutani, MD, MAS, FAAD, joins Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the transition from academia to private practice and playPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 1
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-1/32757/In the first installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, provide an overview of generalized pustular psoriasis, including the unique challenges it poses, triggers associated with it, and the importance ofDermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moNIH Analysis Examines Association Between AD and Comorbidities
https://practicaldermatology.com/programs/practical-dermatology-atopic-dermatitis/nih-analysis-examines-association-between-ad-and-comorbidities/27113/In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a pati